Accessibility Menu
Entrada Therapeutics logo

Entrada Therapeutics(NASDAQ) TRDA

Market Cap$295.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-68%
5 YearN/A
1 Year+43%
1 Month+18%
Premium Feature
Moneyball Superscore
55/100
$7.54
-0.79%
-0.06Today
Entrada Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 7.602026-08-20
Entrada Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.01%USD 7.452026-08-13
1 month+17.65%USD 6.462026-07-21
3 month+15.85%USD 6.562026-05-22
Year to date-26.07%USD 10.282025-12-31
1 year+43.13%USD 5.312025-08-20
3 year-53.37%USD 16.302023-08-21
Since inception-68.27%USD 23.952021-10-29

Entrada Therapeutics Financials at a Glance

Market Cap

$295.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.69M

Net Income (TTM)

-$165.78M

EPS (TTM)

-$3.97

P/E Ratio

-1.92

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$7.54

Volume

38,458.092

Open

$7.64

Previous Close

$7.60

Daily Range

$7.50 - $7.74

52-Week Range

$5.02 - $16.45

Estimated Earnings Date

Nov 5, 2026

TRDA News

Foolcom-Featured.png

Entrada (TRDA) Q2 Revenue Drops 98%

Motley Fool Markets TeamAug 6, 2025

TRDA: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Entrada Therapeutics

Entrada Therapeutics, Inc. makes medicines for rare muscle and eye diseases. These treatments help patients by reaching targets inside cells. The company focuses on treating muscular dystrophy and vision loss.

Targeting Rare Genetic Diseases

  • Duchenne Muscular Dystrophy Franchise: Clinical-stage programs targeting genetic mutations in patients; includes candidates like ENTR-601-44 and ENTR-601-45.
  • Endosomal Escape Vehicle Platform: Proprietary delivery technology designed to transport drugs into cells; supports oligonucleotide, antibody, and enzyme therapies.
  • Myotonic Dystrophy Partnership: Collaboration with Vertex Pharmaceuticals to develop VX-670 for people with myotonic dystrophy type 1, a form of muscular dystrophy.
  • Ocular Disease Programs: Therapies for inherited retinal conditions; includes ENTR-801 for patients with Usher syndrome type 2A.

Recent Strategic Milestones

  • Partnered with Vertex Pharmaceuticals to advance VX-670 through Phase 1/2 clinical trials.
  • Announced ENTR-801 as the first ocular clinical candidate in Dec. 2025.
  • Entered an agreement in Nov. 2025 to potentially sell up to $150.0 million in common stock.
  • Advanced four clinical-stage programs within the Duchenne muscular dystrophy franchise by 2026.

The Edge in Cell Access

Entrada uses its proprietary endosomal escape vehicle technology to reach satellite cells, which are stem cells that help muscles regenerate. This approach aims to repair damaged muscle fibers instead of only slowing down the rate of disease decline.

The Financial Scorecard

  • Cash, cash equivalents, and marketable securities totaled $223.0 million as of June 30, 2026.
  • Collaboration revenue was $1.8 million for the six months ended June 30, 2026.
  • Net loss was $82.5 million for the six months ended June 30, 2026.
  • Market cap was $310.8 million in Q2 2026, up 11.9% year over year.

Path From Research to Clinic

Entrada has evolved from an early research firm into a clinical-stage organization with multiple programs in human trials. Its modular platform allows the company to apply its delivery technology to various rare diseases across muscle and eye tissues.

AI Generated • Aug 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

152

CEO

Dipal Doshi, MBA

Website

www.entradatx.com

Headquarters

Boston, MA 02210, US

TRDA Financials

Key Financial Metrics (TTM)

Gross Margin

-754.72%

Operating Margin

-3767.07%

Net Income Margin

-3537.73%

Return on Equity

-57.61%

Return on Capital

-43.69%

Return on Assets

-55.47%

Earnings Yield

-52.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$295.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

38.94M

Volume

38.46K

Avg. Volume

363.26K

Financials (TTM)

Gross Profit

-$35.37M

Operating Income

-$176.53M

EBITDA

-$164.87M

Operating Cash Flow

-$134.67M

Capital Expenditure

$323.00K

Free Cash Flow

-$134.35M

Cash & ST Invst.

$223.01M

Total Debt

$48.54M

Entrada Therapeutics Performance Analysis

Entrada Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 129,013,000N/A
20242024-12-31USD 210,782,00063.4%
20252025-12-31USD 25,421,000-87.9%
Entrada Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-17.2%
Q42025-12-31-19.5%
Q12026-03-31-32.6%
Q22026-06-302.6%
Entrada Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.0284.5%
20232023-12-31USD -0.20-93.3%
20242024-12-31USD 1.68N/A
20252025-12-31USD -3.47N/A
Entrada Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1.9%
Q42025-12-3110.4%
Q12026-03-31N/A
Q22026-06-30-6.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$898.00K

-53.9%

Gross Profit

$898.00K

-53.9%

Gross Margin

100.00%

N/A

Market Cap

$295.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.95M

N/A

Employees

152

N/A

Net Income

-$42.76M

+0.8%

EBITDA

-$41.89M

+0.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$223.01M

-37.0%

Total Debt

$48.54M

-11.3%

Accounts Receivable

$816.00K

-30.8%

Inventory

$0.00

N/A

Long Term Debt

$44.10M

-10.5%

Short Term Debt

$4.45M

-18.5%

Return on Assets

-55.47%

N/A

Return on Invested Capital

-63.61%

N/A

Free Cash Flow

-$32.47M

-9.1%

Operating Cash Flow

-$32.46M

-10.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VNDAVanda Pharmaceuticals Inc.
$5.34-0.70%
SGMTSagimet Biosciences Inc.
$10.28+0.94%
CAPRCapricor Therapeutics, Inc.
$6.41-6.27%
ARCTArcturus Therapeutics Holdings Inc.
$13.39+21.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$43.52+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.39+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.75+0.10%
MARAMara Holdings
$11.25+0.01%

Questions About TRDA

What is the current price of Entrada Therapeutics?

Entrada Therapeutics is trading at $7.53 per share.

What is the 52-week range for Entrada Therapeutics?

Over the past 52 weeks, Entrada Therapeutics has traded between $5.02 and $16.45.

How much debt does Entrada Therapeutics have?

As of the most recent reporting period, Entrada Therapeutics reported total debt of $48.54M.

How much cash does Entrada Therapeutics have on hand?

Entrada Therapeutics reported $99.28M in cash and cash equivalents in its most recent financial results.

What is Entrada Therapeutics’s dividend yield?

Entrada Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services